Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Jaguar Health (JAGX) Cash & Equivalents (2016 - 2025)

Jaguar Health (JAGX) has disclosed Cash & Equivalents for 11 consecutive years, with $3.5 million as the latest value for Q3 2025.

  • On a quarterly basis, Cash & Equivalents fell 73.42% to $3.5 million in Q3 2025 year-over-year; TTM through Sep 2025 was $3.5 million, a 73.42% decrease, with the full-year FY2024 number at $8.0 million, up 23.7% from a year prior.
  • Cash & Equivalents was $3.5 million for Q3 2025 at Jaguar Health, up from $2.2 million in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $32.2 million in Q1 2021 to a low of $2.2 million in Q2 2025.
  • A 5-year average of $10.9 million and a median of $9.9 million in 2021 define the central range for Cash & Equivalents.
  • Peak YoY movement for Cash & Equivalents: soared 2554.32% in 2021, then crashed 86.25% in 2025.
  • Jaguar Health's Cash & Equivalents stood at $17.1 million in 2021, then tumbled by 67.93% to $5.5 million in 2022, then increased by 18.28% to $6.5 million in 2023, then rose by 23.7% to $8.0 million in 2024, then crashed by 55.92% to $3.5 million in 2025.
  • Per Business Quant, the three most recent readings for JAGX's Cash & Equivalents are $3.5 million (Q3 2025), $2.2 million (Q2 2025), and $5.7 million (Q1 2025).